Merck & Co.(NYSE: $MRK): FDA Approvals & Key Rejection Zone TestMerck & Co. (NYSE: NYSE:MRK ) traded lower at $101.53 after receiving conditional FDA approval for two new cattle antiparasitic treatments—Exzolt Cattle-CA1 and Dectomax-CA1. The approvals target rising cases of New World screwworm larvae and fever ticks, two livestock threats that the FDA says cou
Merck & Co., Inc. Shs Cert Deposito Arg Repr 1/5 Sh
No trades
1.25 USD
15.20 B USD
56.82 B USD
About Merck & Company, Inc.
Sector
Industry
CEO
Robert M. Davis
Website
Headquarters
Rahway
Founded
1891
Identifiers
2
ISIN:ARDEUT110277
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Related stocks
MRK 1H Conservative Short SwingTradeConservative Trade
+ short impulse
+ 1/2 correction
+ BUI test level (exhaustion volume?)
+ weak approach
+ biggest volume Ut?
+ weak test
+ first bearish bar close entry
Calculated affordable virtual stop
(bought puts)
1 to 2 R/R take profit
1D Trend
"+ short impulse
+ short volume distribution
Merck (NYSE: $MRK) Wins EU Approval for Subcutaneous KeytrudaMerck (NYSE: NYSE:MRK ) has secured a major regulatory milestone after the European Commission approved a new subcutaneous version of Keytruda, the company’s flagship cancer therapy. This marks a significant expansion for one of the world’s best-selling immunotherapy drugs, previously only administ
My Take on MRK (Merck & Co.)After a year of falling prices, MRK looks ready to stage a recovery. The stock is now testing the upper range of its consolidation zone — a potential breakout could open the path back toward previous highs.
With strong fundamentals and stellar earnings this year, I’ll be watching closely for a conf
MRK - Merck & Co. | Technical Breakout SetupSymbol: MRK (Merck & Co. Inc.)
Timeframe: Daily/Weekly
Strategy: Breakout Trade - Long Position
🎯 TRADE SETUP
ENTRY: $85.50
STOP LOSS: $78.90
TAKE PROFIT: $98.88
RISK/REWARD: 1:2.1
📊 TECHNICAL ANALYSIS
Trend Structure:
✅ All Timeframes BULLISH (Daily, 4H, 1H)
✅ Price breaking above key resist
MRK - Bear signal bell!=======
Volume
=======
-neutral
==========
Price Action
==========
- Bearish flag noticed
- Weak buying pressure after price gap up
=================
Technical Indicators
=================
- Ichimoku
>>> price above cloud
>>> Green kumo thinning
>>> Tenken + Chiku - above clouds and towards
>
MERCK BULLISH (in long time)
. Overall Setup
The stock has been in a prolonged downtrend (red descending channel), which was broken by a falling wedge pattern (a bullish reversal signal).
After the breakout, price attempted to recover but was rejected around Top 1 – Top 2 (~$86).
It is now pulling back toward a key support zo
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MRK6249696
Merck & Co., Inc. 5.7% 04-DEC-2065Yield to maturity
5.69%
Maturity date
Dec 4, 2065
MRK5584756
Merck & Co., Inc. 5.15% 17-MAY-2063Yield to maturity
5.63%
Maturity date
May 17, 2063
MRK6166087
Merck & Co., Inc. 5.7% 15-SEP-2055Yield to maturity
5.60%
Maturity date
Sep 15, 2055
MRK5319197
Merck & Co., Inc. 2.9% 10-DEC-2061Yield to maturity
5.58%
Maturity date
Dec 10, 2061
MRK6249695
Merck & Co., Inc. 5.55% 04-DEC-2055Yield to maturity
5.56%
Maturity date
Dec 4, 2055
MRK5584755
Merck & Co., Inc. 5.0% 17-MAY-2053Yield to maturity
5.54%
Maturity date
May 17, 2053
MRK4806294
Merck & Co., Inc. 4.0% 07-MAR-2049Yield to maturity
5.48%
Maturity date
Mar 7, 2049
US58933YBF1
Merck & Co., Inc. 2.75% 10-DEC-2051Yield to maturity
5.48%
Maturity date
Dec 10, 2051
MRK5002693
Merck & Co., Inc. 2.45% 24-JUN-2050Yield to maturity
5.47%
Maturity date
Jun 24, 2050
MRK.GF
Merck & Co., Inc. 5.76% 03-MAY-2037Yield to maturity
5.40%
Maturity date
May 3, 2037
MRK6249694
Merck & Co., Inc. 5.5% 15-MAR-2046Yield to maturity
5.38%
Maturity date
Mar 15, 2046
See all MRKC bonds













